Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Dec 2017 10:17

RNS Number : 0902Z
Physiomics PLC
12 December 2017
Β 

12th December 2017

Physiomics plc

("Physiomics") or ("the Company")

Β 

Director Dealing

Β 

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:

Β 

Director

Number of shares sold

Sale price per share

Dr J Millen, CEO

240,000

8.3p

Dr C Chassagnole, COO

600,000

8.3p

Β 

Following the sales of shares, the total holdings of each Director of the Company will be as follows:

Β 

Dr Paul Harper 525,707

Dr Jim Millen 444,641

Dr Christophe Chassagnole 417,008

Β 

The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary share

Β 

Β 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

240,000

d)

Aggregated information

- Aggregated volume

- Price

Β 

240,000

At 8.3p per share

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

Β 

Β 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary share

Β 

Β 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

600,000

d)

Aggregated information

- Aggregated volume

- Price

Β 

600,000

At 8.3p

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

Β 

Β 

Β 

Β 

Β 

Enquiries:

Β 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Β 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

Β 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Β 

Β 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHTTBMTMBBBBIR
Date   Source Headline
7th Jan 20137:00 amRNSRecruitment of Senior Scientist with Clinical PK/P
18th Dec 20129:46 amRNSFrench R&D Tax Credit Accreditation
17th Dec 201212:29 pmRNSResult of AGM
14th Nov 20127:00 amRNSFinal Results for the year ended 30 June 2012
8th Oct 20128:38 amRNSNew US Business Development Consultant
10th Aug 20127:53 amRNSNew Agreement to optimise oncology combination
7th Aug 20123:57 pmRNSStmnt re Share Price Movement
4th Jul 20123:25 pmRNSTrading Update
7th Jun 201211:42 amRNSPresentation at the 2012 PAGE 21st Annual Meeting
29th May 201212:37 pmRNSShare Price Movement
21st May 201212:03 pmRNSDirector/PDMR Shareholding
30th Apr 20127:00 amRNSTotal Voting Rights
26th Apr 20128:49 amRNSIssue of Equity
29th Mar 20127:00 amRNSParticipation in AACR Annual Meeting 2012
16th Mar 20127:00 amRNSPhysiomics to present at the Bio-Europe Conference
7th Mar 20127:00 amRNSHalf Yearly Report
1st Mar 20127:20 amRNSNew Agreement with Global Pharma Company
31st Jan 201211:57 amRNSPhysiomics to enter new therapeutic area
20th Dec 201112:05 pmRNSIssue of Options
18th Nov 201110:07 amRNSResult of AGM
9th Nov 20115:01 pmRNSIssue of Options
2nd Nov 20117:00 amRNSExecution of New Agreement
19th Oct 20117:00 amRNSScientific Board Update
11th Oct 20118:39 amRNSFinal Results
29th Sep 201110:17 amRNSJoint servs alliance executed with Jubilant Biosys
27th May 201110:33 amRNSIssue of Equity
13th May 20114:34 pmRNSIssue of Equity
4th May 20117:00 amRNSNew collaboration with Pharmacometrics Limited
28th Apr 20119:46 amRNSTotal Voting Rights
6th Apr 20117:00 amRNSIssue of Equity
5th Apr 20117:00 amRNSUpcoming Presentation
1st Apr 201110:32 amRNSResults Update
29th Mar 20111:10 pmRNSIssue of Equity
9th Mar 20117:00 amRNSHalf Yearly Report
8th Mar 20117:00 amRNSUpdate: Joint services alliance w. Jubilant Biosys
15th Feb 20114:56 pmRNSStmnt re Share Price Movement
9th Feb 20119:25 amRNSStmnt re Share Price Movement
8th Feb 201111:47 amRNSStmnt re Share Price Movement
7th Feb 20119:42 amRNSIssue of Options
24th Dec 20109:06 amRNSDirector's Notification
13th Dec 201011:07 amRNSResult of AGM
6th Dec 20107:00 amRNSDirectorate Change
15th Nov 20103:23 pmRNSNew Project and Grant Funding
15th Nov 20107:10 amRNSFinal Results for the year ended 30 June 2010
22nd Sep 20103:10 pmRNSRecent Price Movements
31st Aug 20107:01 amRNSJoint Services Alliance with Jubilant Biosys
14th May 201012:08 pmRNSRecent Price Movements and Press Speculation
16th Mar 20107:00 amRNSCollaboration with Sareum, the ICR and CRT
1st Mar 20107:00 amRNSHalf Yearly Report
8th Feb 20104:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.